4.7 Review

Multimorbidity in Older Adults With Cardiovascular Disease

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 71, Issue 19, Pages 2149-2161

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.03.022

Keywords

aging; frailty; multimorbidity; polypharmacy; quality of life

Funding

  1. National Institute on Aging (NIA) [U13AG047008]
  2. American Geriatrics Society
  3. Edwards Lifesciences
  4. Novartis Pharmaceuticals
  5. Pfizer
  6. St. Jude Medical
  7. NIA [P30 AG024827, R56AG051637-01A1, K24AG036778]
  8. VA RR [D F0834 -R, IH-13046787]
  9. Pfizer Inc.
  10. Alnylam Pharmaceuticals Inc.
  11. GSK Inc.
  12. ISIS Pharmaceuticals
  13. Eidos Inc.
  14. Prothena Inc.

Ask authors/readers for more resources

Multimorbidity occurs in adults of all ages, but the number and complexity of comorbid conditions commonly increase with advancing age such that cardiovascular disease (CVD) in older adults typically occurs in a context of multimorbidity. Current clinical practice and research mainly target single disease-specific care that does not embrace the complexities imposed by concurrent conditions. In this paper, emerging concepts regarding CVD in combination with multimorbidity are reviewed, including recommendations for incorporating multimorbidity into clinical decision making, critical knowledge gaps, and research priorities to optimize care of complex older patients. (c) 2018 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available